Fredun Pharmaceuticals Ltd Share Price – BSE

Pharmaceuticals, Small Cap

Fredun Pharmaceuticals has been awarded a significant tender by the Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicines. The total value of the tender ranges between Rs. 15-18 crore. The supply of these goods is set to commence within the first quarter of FY26 and will extend over a period of 14 months.

Commenting on the Development, Fredun Medhora, Managing Director, said: ?We are thrilled to have been awarded this tender by TNMSC. This achievement reflects our ongoing efforts to deliver quality healthcare solutions and our commitment to serving the needs of the public health sector. We look forward to a successful collaboration with TNMSC and to making a positive impact on the healthcare landscape in Tamil Nadu.

Powered by Capital Market - Live News

Fredun Pharmaceuticals announced its foray into the large animal veterinary segment, under the FREOSSI Large Animals brand with the launch of targeted products Freossi Tone+ and Freossi Power. FREOSSI has a strong & existing reputation in companion animal care, hence this will provide a foundation of trust and reliability when expanding into large animal products.

These new products have scientific & clinical evidence and are developed with the expertise of veterinary professionals in animal health. They specifically are designed to address key health challenges faced by livestock owners including lactation issues, quality of milk, joint stiffness, and mobility concerns.

Commenting on the Development, Fredun Medhora, Managing Director, said: “Our foray into the large animal healthcare space is a strategic step in expanding Fredun Pharma's presence in veterinary healthcare, while reinforcing our commitment to innovation and quality. With Freossi Tone + and Freossi Power, we are addressing key challenges faced by livestock owners while promoting the overall advancement of animal health. This marks an important milestone as we work towards offering specialized solutions across the broader veterinary spectrum.”

Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 26.30% to Rs 5.33 crore in the quarter ended December 2024 as against Rs 4.22 crore during the previous quarter ended December 2023. Sales rose 17.53% to Rs 101.84 crore in the quarter ended December 2024 as against Rs 86.65 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Fredun Pharmaceuticals announced its foray into the large animal veterinary segment, under the FREOSSI Large Animals brand with the launch of targeted products Freossi Tone+ and Freossi Power. FREOSSI has a strong & existing reputation in companion animal care, hence this will provide a foundation of trust and reliability when expanding into large animal products.

These new products have scientific & clinical evidence and are developed with the expertise of veterinary professionals in animal health. They specifically are designed to address key health challenges faced by livestock owners including lactation issues, quality of milk, joint stiffness, and mobility concerns.

Commenting on the Development, Fredun Medhora, Managing Director, said: “Our foray into the large animal healthcare space is a strategic step in expanding Fredun Pharma's presence in veterinary healthcare, while reinforcing our commitment to innovation and quality. With Freossi Tone + and Freossi Power, we are addressing key challenges faced by livestock owners while promoting the overall advancement of animal health. This marks an important milestone as we work towards offering specialized solutions across the broader veterinary spectrum.”

Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 26.30% to Rs 5.33 crore in the quarter ended December 2024 as against Rs 4.22 crore during the previous quarter ended December 2023. Sales rose 17.53% to Rs 101.84 crore in the quarter ended December 2024 as against Rs 86.65 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 February 2025.

Powered by Capital Market - Live News

Fredun Pharmaceuticals has been awarded a significant tender by the Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicines. The total value of the tender ranges between Rs. 15-18 crore. The supply of these goods is set to commence within the first quarter of FY26 and will extend over a period of 14 months.

Commenting on the Development, Fredun Medhora, Managing Director, said: ?We are thrilled to have been awarded this tender by TNMSC. This achievement reflects our ongoing efforts to deliver quality healthcare solutions and our commitment to serving the needs of the public health sector. We look forward to a successful collaboration with TNMSC and to making a positive impact on the healthcare landscape in Tamil Nadu.

Powered by Capital Market - Live News

Fredun Pharmaceuticals announced its foray into the large animal veterinary segment, under the FREOSSI Large Animals brand with the launch of targeted products Freossi Tone+ and Freossi Power. FREOSSI has a strong & existing reputation in companion animal care, hence this will provide a foundation of trust and reliability when expanding into large animal products.

These new products have scientific & clinical evidence and are developed with the expertise of veterinary professionals in animal health. They specifically are designed to address key health challenges faced by livestock owners including lactation issues, quality of milk, joint stiffness, and mobility concerns.

Commenting on the Development, Fredun Medhora, Managing Director, said: “Our foray into the large animal healthcare space is a strategic step in expanding Fredun Pharma's presence in veterinary healthcare, while reinforcing our commitment to innovation and quality. With Freossi Tone + and Freossi Power, we are addressing key challenges faced by livestock owners while promoting the overall advancement of animal health. This marks an important milestone as we work towards offering specialized solutions across the broader veterinary spectrum.”

Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 26.30% to Rs 5.33 crore in the quarter ended December 2024 as against Rs 4.22 crore during the previous quarter ended December 2023. Sales rose 17.53% to Rs 101.84 crore in the quarter ended December 2024 as against Rs 86.65 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Fredun Pharmaceuticals announced its foray into the large animal veterinary segment, under the FREOSSI Large Animals brand with the launch of targeted products Freossi Tone+ and Freossi Power. FREOSSI has a strong & existing reputation in companion animal care, hence this will provide a foundation of trust and reliability when expanding into large animal products.

These new products have scientific & clinical evidence and are developed with the expertise of veterinary professionals in animal health. They specifically are designed to address key health challenges faced by livestock owners including lactation issues, quality of milk, joint stiffness, and mobility concerns.

Commenting on the Development, Fredun Medhora, Managing Director, said: “Our foray into the large animal healthcare space is a strategic step in expanding Fredun Pharma's presence in veterinary healthcare, while reinforcing our commitment to innovation and quality. With Freossi Tone + and Freossi Power, we are addressing key challenges faced by livestock owners while promoting the overall advancement of animal health. This marks an important milestone as we work towards offering specialized solutions across the broader veterinary spectrum.”

Powered by Capital Market - Live News

Net profit of Fredun Pharmaceuticals rose 26.30% to Rs 5.33 crore in the quarter ended December 2024 as against Rs 4.22 crore during the previous quarter ended December 2023. Sales rose 17.53% to Rs 101.84 crore in the quarter ended December 2024 as against Rs 86.65 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

Fredun Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 4 February 2025.

Powered by Capital Market - Live News